Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on Plaintiffs’ Request to Unseal Key Clinical Studies Data

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

The plaintiffs in these cases allege that Risperdal causes gynecomastia, which is the enlargement of breast tissue in males.

(PRWEB) December 14, 2013

Risperdal plaintiffs have asked a Pennsylvania judge to unseal clinical studies data, citing its importance to the public interest, according to court documents. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the documents detail potential risks associated with the antipsychotic drug.

The request from attorneys representing plaintiffs in about 300 Pennsylvania state Risperdal lawsuits is a response to an initial request from Johnson & Johnson and subsidiary Janssen Pharmaceuticals to uphold a 2011 order to keep the documents sealed, according to court documents (In re: Risperdal Litigation; Case No. 100300296, Philadelphia Court of Common Pleas, Pennsylvania.)

J&J previously argued that because the documents are generated for researchers and regulators, and not for the general public, there is no reason to unseal them, according to court documents.

“The plaintiffs in these cases allege that Risperdal causes gynecomastia, which is the enlargement of breast tissue in males,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “They believe the sealed data speaks to their allegations, and so they are requesting that the courts order the documents to be made available.”

Recently, J&J agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities, according to a Nov. 4 New York Times story.* The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega. The federal government alleges that J&J marketed the drug to high-risk groups from 1999 to 2005, the story said. Part of the settlement includes J&J’s pleading guilty to a criminal misdemeanor for its role in promotion of the drug to those groups.

Risperdal has been shown to almost double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
plus.google.com/106070664376281033016